In a multicenter study, significant differences in long-term survival were observed between patients with Epstein-Barr virus-associated gastric cancer (EBVAGC) and those with Epstein-Barr virus-negative gastric cancer (EBVNGC) after radical gastrectomy. The 3-year overall and disease-free survival rates were notably higher in the EBVAGC group. Additionally, positivity for Epstein-Barr virus-encoded small RNA served as an independent predictor of survival, and it’s essential for stage II and III patients to receive at least four cycles of chemotherapy postoperatively.
Journal Article by Xie RZ, Huang ZN (…) Li P et 8 al. in Eur J Surg Oncol
Copyright © 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.